CLSA Remains Positive on China's Biopharmaceutical Sector, Prefers INNOVENT BIO and SKB BIOAASTOCKS News·Nov 18, 2026 at 07:58 AM01801-2.68%
CSPC Pharmaceutical Group: Revenue, licensing income and pipeline milestones advanced alongside a 73.6% 1-9M gross marginQuartr·Nov 18, 2026 at 06:51 AM01093+1.20%
CMBI Cuts AKESO TP to HKD99.34; HARMONi-3 Remains Key CatalystAASTOCKS News·Nov 18, 2026 at 05:48 AM09926-4.68%
Innovent Biologics (IVBXF) Receives a Buy from Huatai SecuritiesTip Ranks·Nov 18, 2026 at 05:05 AM01801-2.68%
CSPC Reports Nine-Month Revenue and Profit Growth in 2026Tip Ranks·Nov 18, 2026 at 04:38 AM01093+1.20%
CMBI Raises SBP GROUP TP to HKD9 as Multiple Innovative Drugs Included in National Medical InsuranceAASTOCKS News·Nov 18, 2026 at 04:23 AM01177-0.82%
CSPC Pharmaceutical Group: AstraZeneca licence income and finished-drug growth lifted 9M revenue 27% and profit 101.5%Quartr·Nov 18, 2026 at 04:14 AM01093+1.20%
BeOne Medicines: Five solid-tumor programs advance as strong cash flow funds continued pipeline investmentQuartr·Nov 17, 2026 at 11:07 AMONC+0.48%06160-1.05%
Innovent Says Takeda Wins Japan SAKIGAKE Designation for Gastric Cancer Drug Arcotatug TavatecanPUBT·Nov 17, 2026 at 08:30 AMTAK+0.23%01801-2.68%
UBS: Johnson & Johnson's Acquisition of Ollin Validates INNOVENT BIO Ophthalmology R&DAASTOCKS News·Nov 17, 2026 at 05:27 AMJNJ-1.36%01801-2.68%
China Accepts Akeso’s Ivonescimab Application for Biliary Tract CancerPUBT·Nov 17, 2026 at 03:31 AM09926-4.68%